Altered small-world properties of gray matter networks in breast cancer

BMC Neurology

Volumn 12, Issue , 2012, Pages

  Hosseini, S M H ^a   Koovakkattu, Della ^a   Kesler, Shelli R ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN FUNCTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVOR; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; FRONTAL LOBE; GRAPH THEORETICAL ANALYSIS; GRAY MATTER; HUMAN; MEDICAL HISTORY; MEMORY DISORDER; NERVE CELL NETWORK; STATISTICAL ANALYSIS; TEMPORAL LOBE; BIOLOGICAL MODEL; BREAST TUMOR; COMPUTER SIMULATION; MIDDLE AGED; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPUTER SIMULATION; FEMALE; HUMANS; MIDDLE AGED; MODELS, NEUROLOGICAL; NERVE NET; NEURONS;

EID: 84861441781     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-12-28     Document Type: Article

References (61)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics 2011, a cancer journal for clinicians, CA.
2. Vardy J. Cognitive function in breast cancer survivors. Cancer Treat Res 2009, 151:387-419. 10.1007/978-0-387-75115-3_24, 19593525.
3. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 2011, 38:431-438. 10.1053/j.seminoncol.2011.03.014, 3120018, 21600374.
4. Kesler SR, Kent J, O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 2011, 68:1447-1453. 10.1001/archneurol.2011.245, 3239218, 22084128.
5. Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA. Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve. J Clin Oncol 2010, 28:4434-4440. 10.1200/JCO.2009.27.0827, 2988635, 20837957.
6. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009, 116:113-123. 10.1007/s10549-008-0114-2, 18629633.
7. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006, 98:1742-1745. 10.1093/jnci/djj470, 17148777.
8. Jansen CE, Cooper BA. Dodd MJ 2010, A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer, Miaskowski CA.
9. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010, 116:3348-3356. 10.1002/cncr.25098, 20564075.
10. de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, Nederveen AJ, Boven E, Schagen SB. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 2011, 32:1206-1219. 10.1002/hbm.21102, 20669165.
11. Wefel JS, Witgert ME, Meyers CA. Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. Neuropsychol Rev 2008, 18:121-131. 10.1007/s11065-008-9058-x, 18415683.
12. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7:192-201. 10.1038/nrc2073, 3329763, 17318212.
13. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009, 62:42-52. 10.1016/j.neuron.2009.03.024, 2691647, 19376066.
14. Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, Smeets A, Christiaens MR, Leemans A, Van Hecke W, et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 2011, 32:480-493. 10.1002/hbm.21033, 20725909.
15. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 2010, 123:819-828. 10.1007/s10549-010-1088-4, 20690040.
16. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, Wada N, Imoto S, Murakami K, Uchitomi Y. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007, 109:146-156. 10.1002/cncr.22368, 17131349.
17. Abraham J, Haut M, Moran M, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008, 8:88-91. 10.3816/CBC.2008.n.007, 18501063.
18. Leh SE, Petrides M, Strafella AP. The Neural Circuitry of Executive Functions in Healthy Subjects and Parkinson's Disease. Neuropsychopharmacology 2010, 35:70-85. 10.1038/npp.2009.88, 3055448, 19657332.
19. Bakkum-Gamez JN, Laughlin SK, Jensen JR, Akogyeram CO, Pruthi S. Challenges in the Gynecologic Care of Premenopausal Women With Breast Cancer. Mayo Clin Proc 2011, 86:229-240. 10.4065/mcp.2010.0794, 3046944, 21307388.
20. Bassett DS, Bullmore E. Small-world brain networks. Neuroscientist 2006, 12:512-523. 10.1177/1073858406293182, 17079517.
21. Simard D, Nadeau L. Fastest learning in small-world neural networks. Physics Letters A 2005, 336:8-15.
22. Fan Y, Shi F, Smith JK, Lin W, Gilmore JH, Shen D. Brain anatomical networks in early human brain development. NeuroImage 2011, 54:1862-1871. 10.1016/j.neuroimage.2010.07.025, 3023885, 20650319.
23. Chen ZJ, He Y, Rosa-Neto P, Germann J, Evans AC. Revealing modular architecture of human brain structural networks by using cortical thickness from MRI. Cerebral cortex 2008, 18:2374-2381. 10.1093/cercor/bhn003, 2733312, 18267952.
24. Petrella JR. Use of graph theory to evaluate brain networks: a clinical tool for a small world?. Radiology 2011, 259:317-320. 10.1148/radiol.11110380, 21502388.
25. Sporns O, Chialvo DR, Kaiser M, Hilgetag CC. Organization, development and function of complex brain networks. Trends Cogn Sci 2004, 8:418-425. 10.1016/j.tics.2004.07.008, 15350243.
26. Bassett DS, Bullmore E, Verchinski BA, Mattay VS, Weinberger DR, Meyer-Lindenberg A. Hierarchical organization of human cortical networks in health and schizophrenia. J Neurosci 2008, 28:9239-9248. 10.1523/JNEUROSCI.1929-08.2008, 2878961, 18784304.
27. Bernhardt BC, Chen Z, He Y, Evans AC, Bernasconi N. Graph-Theoretical Analysis Reveals Disrupted Small-World Organization of Cortical Thickness Correlation Networks in Temporal Lobe Epilepsy. Cerebral Cortex 2011, 21(9):2147-2157. 10.1093/cercor/bhq291, 21330467.
28. He Y, Chen Z, Evans A. Structural insights into aberrant topological patterns of large-scale cortical networks in Alzheimer's disease. J Neurosci 2008, 28:4756-4766. 10.1523/JNEUROSCI.0141-08.2008, 18448652.
29. Wu K, Taki Y, Sato K, Kinomura S, Goto R, Okada K, Kawashima R, He Y, Evans AC, Fukuda H. Age-related changes in topological organization of structural brain networks in healthy individuals. Hum Brain Mapp 2011, 33(3):552-568.
30. He Y, Dagher A, Chen Z, Charil A, Zijdenbos A, Worsley K, Evans A. Impaired small-world efficiency in structural cortical networks in multiple sclerosis associated with white matter lesion load. Brain 2009, 132:3366-3379. 10.1093/brain/awp089, 2792366, 19439423.
31. Lowe DA, Rogers SA. Estimating Premorbid Intelligence among Older Adults: The Utility of the AMNART. J Aging Res 2011, 2011:428132. 3100635, 21629758.
32. Wilke M, Holland S, Altaye M, Gaser C. Template-O-Matic: A toolbox for creating customized pediatric templates. NeuroImage 2008, 41:903-913. 10.1016/j.neuroimage.2008.02.056, 18424084.
33. Ashburner J, Friston KJ. Unified segmentation. NeuroImage 2005, 26:839-851. 10.1016/j.neuroimage.2005.02.018, 15955494.
34. Zalesky A, Fornito A, Harding IH, Cocchi L, Yucel M, Pantelis C, Bullmore ET. Whole-brain anatomical networks: does the choice of nodes matter?. NeuroImage 2010, 50:970-983. 10.1016/j.neuroimage.2009.12.027, 20035887.
35. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 2002, 15:273-289. 10.1006/nimg.2001.0978, 11771995.
36. He Y, Chen ZJ, Evans AC. Small-world anatomical networks in the human brain revealed by cortical thickness from MRI. Cerebral cortex 2007, 17:2407-2419.
37. van Wijk BC, Stam CJ, Daffertshofer A. Comparing brain networks of different size and connectivity density using graph theory. PLoS One 2010, 5:e13701. 10.1371/journal.pone.0013701, 2965659, 21060892.
38. Rubinov M, Sporns O. Complex network measures of brain connectivity: uses and interpretations. NeuroImage 2010, 52:1059-1069. 10.1016/j.neuroimage.2009.10.003, 19819337.
39. Maslov S, Sneppen K. Specificity and stability in topology of protein networks. Science 2002, 296:910-913. 10.1126/science.1065103, 11988575.
40. Milo R, Shen-Orr S, Itzkovitz S, Kashtan N, Chklovskii D, Alon U. Network motifs: simple building blocks of complex networks. Science 2002, 298:824-827. 10.1126/science.298.5594.824, 12399590.
41. Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic functional brain connectivity in Alzheimer's disease. PLoS Comput Biol 2008, 4:e1000100. 10.1371/journal.pcbi.1000100, 2435273, 18584043.
42. Sailer M, Fischl B, Salat D, Tempelmann C, Schoenfeld MA, Busa E, Bodammer N, Heinze HJ, Dale A. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003, 126:1734-1744. 10.1093/brain/awg175, 12805100.
43. Sepulcre J, Goni J, Masdeu JC, Bejarano B, Velez N, Toledo JB, Villoslada P. Contribution of white matter lesions to gray matter atrophy in multiple sclerosis. Arch Neurol 2009, 66:173-179. 10.1001/archneurol.2008.562, 19204153.
44. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5:22. 10.1186/jbiol50, 2000477, 17125495.
45. Seigers R, Schagen SB, Beerling W, Boogerd W, van Tellingen O, van Dam FS, Koolhaas JM, Buwalda B. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008, 186:168-175. 10.1016/j.bbr.2007.08.004, 17854921.
46. Winocur G, Vardy J, Binns MA, Kerr L, Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006, 85:66-75. 10.1016/j.pbb.2006.07.010, 16935324.
47. Han R, Yang YM, Dietrich J, Luebke A. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008, 7(4):12. 10.1186/jbiol69, 2397490, 18430259.
48. Seigers R, Schagen SB, Coppens CM, van der Most PJ, van Dam FS, Koolhaas JM, Buwalda B. Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behav Brain Res 2009, 201:279-284. 10.1016/j.bbr.2009.02.025, 19428645.
49. Sporns O. The human connectome: a complex network. Annals NewYork Academy Sci 2011, 1224:109-25.
50. Kesler SR, Bennett FC, Mahaffey ML, Spiegel D. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res 2009, 15:6665-6673. 10.1158/1078-0432.CCR-09-1227, 2859687, 19843664.
51. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007, 103:303-311. 10.1007/s10549-006-9380-z, 17009108.
52. Samatovicz RA. Genetics and brain injury: apolipoprotein E. J head trauma rehab 2000, 15:869-874.
53. Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, Mott LA. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology 2003, 12:612-619. 10.1002/pon.742, 12923801.
54. Krabbe KS, Reichenberg A, Yirmiya R, Smed A, Pedersen BK, Bruunsgaard H. Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun 2005, 19:453-460. 10.1016/j.bbi.2005.04.010, 15963684.
55. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc 2002, 50:2041-2056. 10.1046/j.1532-5415.2002.50619.x, 12473019.
56. Aalto S, Bruck A, Laine M, Nagren K, Rinne JO. Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11 C]FLB 457. J neurosci official j Soc Neurosci 2005, 25:2471-2477.
57. Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006, 24:675-680. 10.1200/JCO.2005.02.3515, 16446340.
58. Boulware MI, Kent BA, Frick KM. The Impact of Age-Related Ovarian Hormone Loss on Cognitive and Neural Function. Curr Top Behav Neurosci 2012, 10:165-184.
59. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004, 26:955-969. 10.1080/13803390490510905, 15742545.
60. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen- and tamoxifen-associated effects on brain structure and function. NeuroImage 2004, 21:364-371. 10.1016/j.neuroimage.2003.08.037, 14741674.
61. Poreh A. The Quantified Process Approach to Neuropsychological Assessment 2006, Taylor and Francis, New York, NY.